Navigation Links
Ovarian cancer study offers vital clues for new therapies
Date:4/21/2010

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

Researchers have found that patients with hereditary ovarian cancer whose tumours are caused by faulty genes are more likely to experience secondary tumours in their liver and spleen. This is despite the fact that their overall prognosis is better than other patients.

In non-hereditary cancer, ovarian tumours tend to remain within the lining of the abdomen and pelvis.

A University of Edinburgh study suggests that ovarian cancer patients whose tumours spread to the solid organs such as the liver and lungs should be tested for the faulty genes BRCA1 and BRCA2 to ensure they are given the most appropriate treatment.

Researchers say this would improve the detection of these faulty genes as current criteria for genetic testing may miss as many as two-thirds of ovarian cancer patients carrying faulty BRCA genes.

Patients with hereditary tumours, which account for 10 per cent of ovarian cancers, may also be suitable for trials of a new drug called olaparib, which has fewer side-effects than normal cancer treatments.

Improving the identification of BRCA mutations would help relatives of ovarian cancer patients, who may themselves be at increased risk of developing hereditary cancer.

The research is published in the Journal of Clinical Oncology.

Dr Charlie Gourley, who led the research at the University of Edinburgh, said: "We are beginning to understand the importance of tailoring cancer treatments according to the specifics of each patient's tumour. These findings demonstrate that tumours which arise because of defects in the BRCA1 or BRCA2 genes behave differently to other ovarian cancers. This information should also help us to identify the patients carrying these genetic mutations, give them the most effective treatment for their cancer and offer their relatives genetic counselling."


'/>"/>

Contact: Anna Borthwick
anna.borthwick@ed.ac.uk
44-131-651-4400
University of Edinburgh
Source:Eurekalert

Related medicine news :

1. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
2. Pre-Diagnosis Diet Linked to Ovarian Cancer Survival
3. Study finds delay in referrals for older women with ovarian cancer
4. Foster Friess commits up to $50,000 to help TGen fight ovarian cancer
5. How to make the best decisions when at high risk for breast or ovarian cancer
6. Symptoms have little value for early detection of ovarian cancer
7. Symptoms Alone Dont Spot Ovarian Cancer Early
8. Ultrasound plus proteomic blood analyses may help physicians diagnose early-stage ovarian cancer
9. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
10. Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene (BRCA1)
11. Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known ... for in a show called "Front Page". One of the forthcoming episodes examines mammogram ... rates have plummeted in large part due to early detection. Like any other disease, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Findings from ... safety of CTL019, an investigational chimeric antigen receptor ... pediatric and young adult patients with B-cell acute ... an oral session at the 58th American Society ... 3, 4:00-5:30 p.m.). The global Phase II study ...
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical Laboratories, ... de la Compañía, el INSTI HIV Self Test , a los miembros ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
Breaking Medicine Technology: